aceProfluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI
Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...
Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.
Evidence
- JournalismMarketScreener2026-09-30
How should this claim be treated?
Truvace Impact Record TRV-2026-1229, v1: “Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI.” Truvace, 2026-10-01. /record/TRV-2026-1229 (accessed at citation time). sha256 8507a350b89fd66b…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1229 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.